Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity - 2Fiber is something most people could use more of. But experts advise caution with 'fibermaxxing'
- 3How is 'A Knight of the Seven Kingdoms' connected to 'Game of Thrones'?
- 4Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- 5The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- The race is on to turn your body into a GLP-1 factory
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Figure out How to Track the Establishment of New 5G Pinnacles
- Must-See Attractions in France
- 'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- Monetary Versatility: Get ready for Life's Unforeseen Difficulties
- Astronauts head home early after medical issue
- 5 Movies That Leaving an Imprint with Inventive Innovation
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
